Institut Claudius Regaud
Toulouse, France
30 recruiting
Showing 1–20 of 46 trials
Recruiting
Phase 1Phase 2
A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
Metastatic Breast CancerLocally Advanced Breast CancerUnresectable Breast Carcinoma
BioNTech SE380 enrolled68 locationsNCT06827236
Recruiting
Phase 1Phase 2
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Breast CancerTriple-Negative Breast CancerColorectal, Cancer+26 more
PMV Pharmaceuticals, Inc300 enrolled77 locationsNCT04585750
Recruiting
Phase 2
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Breast CancerEsophageal CancerGastric Cancer+11 more
Daiichi Sankyo740 enrolled85 locationsNCT06172478
Recruiting
Routine Shallow-coverage Whole Genome Sequencing Testing of Liquid-based Cervical Smears for the Early Diagnosis of Ovarian Cancer
Cervical Cancer ScreeningHigh Grade Serous Ovarian CancerWhole Genome Sequencing+1 more
Institut Claudius Regaud50 enrolledNCT07821879
Recruiting
Phase 1Phase 2
A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas
Relapsed/Refractory Non-Hodgkin Lymphoma
Bristol-Myers Squibb460 enrolled67 locationsNCT06090539
Recruiting
Phase 1Phase 2
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
Breast NeoplasmsBreast DiseasesNeoplasms+5 more
Stemline Therapeutics, Inc.73 enrolled86 locationsNCT05386108
Recruiting
Phase 3
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
Breast CancerMetastatic Breast CancerHER2-negative Breast Cancer+3 more
Relay Therapeutics, Inc.540 enrolled211 locationsNCT06982521
Recruiting
Phase 3
A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study
Cancer
Hoffmann-La Roche100 enrolled67 locationsNCT05862285
Recruiting
Phase 1
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
Relapsed or Refractory Multiple MyelomaPreviously Treated Amyloid Light-chain (AL) Amyloidosis
Janssen Research & Development, LLC180 enrolled29 locationsNCT05652335
Recruiting
Phase 1
A Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies
Hematologic Neoplasms
Janssen Research & Development, LLC360 enrolled8 locationsNCT07572006
Recruiting
Phase 1
A Study of JNJ-90189892 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms
Leukemia, Myeloid, AcuteMyelodysplastic Neoplasms
Janssen Research & Development, LLC155 enrolled9 locationsNCT06651229
Recruiting
Phase 3
EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma
Glioblastoma
NovoCure GmbH741 enrolled102 locationsNCT06556563
Recruiting
Phase 1Phase 2
First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors
Advanced Solid TumorMetastatic Solid Tumor
Daiichi Sankyo590 enrolled33 locationsNCT05875168
Recruiting
Phase 1Phase 2
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
Recurrent or Metastatic Solid Tumors
Daiichi Sankyo680 enrolled119 locationsNCT06330064
Recruiting
Phase 3
Study on the Efficacy of Treatment by Radiotherapy and Pembrolizumab in Newly Diagnosed Metastatic Head & Neck Cancers
Squamous Cell Carcinoma of Head and Neck
UNICANCER102 enrolled26 locationsNCT04747054
Recruiting
French Childhood Cancer Survivor Study
Childhood Solid Tumor
Institut National de la Santé Et de la Recherche Médicale, France18,000 enrolled36 locationsNCT01620372
Recruiting
Phase 2
Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatment
Malignant Solid Neoplasms
Centre Leon Berard900 enrolled7 locationsNCT02029001
Recruiting
Phase 3
Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer
Endometrial Cancer
Daiichi Sankyo710 enrolled75 locationsNCT07022483
Recruiting
Phase 2
Pembrolizumab and Chemotherapy Treatment or no Treatment Guided by the Level of TILs in Resected Early-stage TNBC
Triple-Negative Breast Cancer
UNICANCER354 enrolled44 locationsNCT06078384
Recruiting
Phase 2
A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors.
Malignant Solid Tumor
Centre Leon Berard455 enrolled13 locationsNCT04116541